Positive and Negative Predictive Value of a Non-Endoscopic Molecular Barrett’s Esophagus Detection Test in Screening Eligible Adults: Results from a Large Multicenter Population Based Clinical Trial ...
The Cologuard Plus test demonstrated 95% sensitivity for colorectal cancer detection at 94% specificity, making it the most accurate noninvasive CRC screening test reported in studies to date Building ...
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced an expanded partnership with Humana Inc. to enhance ...
MADISON (WKOW) — Exact Sciences has launched its new "Cologuard Plus" test. This test is gaining attention as the most accurate non-invasive colorectal screening test currently available. The ...
Exact Sciences Corporation EXAS is focused on further promoting Cologuard as the standard of care. The company prioritizes high-return pipeline opportunities with large patient impacts, which is ...
Hosted on MSN
Exact Sciences raises 2025 revenue guidance to $3.235B amid Cologuard Plus expansion and Cancerguard launch
Bloomer announced, "We are raising total full year revenue to between $3.22 billion and $3.235 billion, an increase of $78 million at midpoint. This includes screening revenue between $2.51 billion ...
Mark Stenhouse left his executive role at AbbVie to join Exact Sciences because he felt the company was fighting a worthy battle: preventing colorectal cancer. Mr. Stenhouse, now Exact Science’s ...
Exact Sciences reported $268.9 million in revenue for the second quarter ended June 30, but still had a net loss of $86.1 million. Here are four quotes from Exact’s leadership team on the company’s ...
(RTTNews) - Exact Sciences Corp. (EXAS) Monday has introduced Cologuard Plus, an FDA-approved noninvasive colorectal cancer - CRC screening test for average-risk adults aged 45 and older. It offers 95 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback